Easily characterize the interactions you need to translate in vitro activity to in vivo drug efficacy with label-free Agile R100. The understanding of protein-protein interactions is vital to the understanding of disease mechanisms and potential therapeutics. Field Effect Biosensing (FEB) is a label-free technique that enables protein characterization without the use of labels that can produce unwanted interactions that can lead to false conclusions. FEB biosensors such as Agile R100, eliminate the need for tags, dyes, or other specialized materials, reducing resources needed for assay development and simplifying assay design.
Agile R100 features:
- High-quality quantitative kinetic analysis including, kon, koff, and KD
- Detection in cell or tissue lysate, serum, or DMSO
- High sensitivity down to 100 fM, enabling detection of tight-binding compounds
- Fast measurements that enable quick kinetic characterization of unstable proteins
- Just a 10 µL drop of sample enables more data with less material
- Reusable Agile biosensor chips provide up to 10 measurements each
Technical Note: Kinetic Binding Analysis on Agile R100
- Publication including below figures: Qvit, N., et al.  Angewandte Chemie
- Publication: FEB Increases Signal-to-Noise by 10 Times versus BLI and ELISA
The figures above show binding activity and selectivity of peptides in vitro, with data taken by Agile R100. The first figure shows the selectivity of dPKC and ePKC binding to yMARCKS-Cargo. The second figure shows a dose-response curve of dPKC binding to yMARCKS-Cargo. Additional info can be found in the Qvit publication in the downloadable literature section.